Jay C Wang, MD
Ophthalmology · Monterey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 34
- 9 carriers
- Offices
- 5
Offices
5 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
34 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
34 of 34 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A174746 · Current
Licensed to practise in California · since 2021 · expires 2027-09-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$2,545,422
Medicare paid this office $2,545,422 for 877 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 181 | $1,091,102 | None |
| Injection, faricimab-svoa, 0.1 mg | 95 | $881,133 | None |
| Injection of drug into eye | 282 | $146,362 | $109 |
| Imaging of retina | 823 | $95,576 | $38 |
| Established patient problem focused exam of visual system | 441 | $60,316 | $91 |
See all 14 services
| Injection, aflibercept, 1 mg | 181 | $1,091,102 | None |
| Injection, faricimab-svoa, 0.1 mg | 95 | $881,133 | None |
| Injection of drug into eye | 282 | $146,362 | $109 |
| Imaging of retina | 823 | $95,576 | $38 |
| Established patient problem focused exam of visual system | 441 | $60,316 | $91 |
| Established patient complete exam of visual system | 525 | $58,759 | $109 |
| Short return visit (20+ min) | 213 | $18,124 | $65 |
| New patient complete exam of visual system | 136 | $17,880 | $131 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 96 | $16,601 | $161 |
| Return visit (30+ min) | 97 | $14,107 | $116 |
| New patient visit (45+ min) | 69 | $10,685 | $155 |
| Photography of the retina | 113 | $4,680 | $33 |
| Compounded drug, not otherwise classified | 18 | $2,815 | None |
| 2d ultrasound scan of eye tissue and structures | 25 | $2,381 | $48 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
877 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 24% · Women 58% · Also on Medicaid 24% · Health risk score 1.39. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 35% · Coronary heart disease 28% · Chronic kidney disease 23% · Cancer 16% · Atrial fibrillation 16% · Heart failure 15% · Depression 14% · COPD 11% · Stroke 9% · Dementia 7%.
The office billed $7,726,160, Medicare allowed $3,248,093 and paid $2,545,422; for 41,725 services of 46 kinds; $2,052,183 of it was for drugs given in the office and $493,238 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 877 | 41,725 | 78 | 1.39 | $7,726,160 | $2,545,422 |
| 2023 | 827 | 25,131 | 78 | 1.28 | $6,783,934 | $2,329,515 |
| 2022 | 731 | 9,585 | 78 | 1.24 | $5,555,362 | $2,001,727 |
| 2021 | 407 | 1,936 | 76 | 1.41 | $1,278,524 | $407,154 |
| 2020 | 162 | 470 | 71 | 2.01 | $323,276 | $64,717 |
| 2019 | 146 | 246 | 72 | 1.71 | $126,439 | $22,334 |
| 2018 | 63 | 101 | 71 | 1.01 | $48,463 | $10,649 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Injection, aflibercept, 1 mg | 209 | $1,357,796 | None |
| Injection, faricimab-svoa, 0.1 mg | 56 | $456,928 | None |
| Injection of drug into eye | 276 | $132,481 | $104 |
| Imaging of retina | 791 | $86,495 | $37 |
| Short return visit (20+ min) | 477 | $59,501 | $73 |
| Established patient complete exam of visual system | 230 | $27,066 | $116 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 161 | $23,513 | $138 |
| New patient complete exam of visual system | 176 | $22,225 | $126 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 14 | $17,963 | $1,123 |
| New patient visit (45+ min) | 126 | $16,717 | $133 |
| Return visit (30+ min) | 102 | $13,691 | $111 |
| Repair of detached retina by injection of air or gas | 11 | $10,225 | $852 |
| Destruction of leaking blood vessels of retina using laser | 11 | $8,279 | $436 |
| Compounded drug, not otherwise classified | 20 | $5,992 | None |
| Photography of the retina | 83 | $3,474 | $32 |
| 2d ultrasound scan of eye tissue and structures | 30 | $2,772 | $47 |
| Long return visit (40+ min) | 12 | $2,035 | $170 |
2022: 18 services
| Injection, aflibercept, 1 mg | 196 | $1,465,481 | None |
| Injection of drug into eye | 234 | $113,217 | $102 |
| Imaging of retina | 702 | $77,289 | $36 |
| Injection, ranibizumab, 0.1 mg | 17 | $62,785 | None |
| Injection, faricimab-svoa, 0.1 mg | 16 | $59,086 | None |
| Short return visit (20+ min) | 394 | $56,920 | $76 |
| New patient complete exam of visual system | 205 | $25,143 | $123 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 142 | $19,129 | $123 |
| New patient visit (45+ min) | 147 | $17,303 | $118 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 15 | $15,524 | $1,035 |
| Established patient complete exam of visual system | 135 | $13,453 | $99 |
| Return visit (30+ min) | 75 | $9,216 | $106 |
| Removal of eye fluid (vitreous) between lens and retina | 11 | $9,058 | $755 |
| Destruction of leaking blood vessels of retina using laser | 11 | $5,296 | $353 |
| Compounded drug, not otherwise classified | 18 | $2,877 | None |
| Photography of the retina | 51 | $2,313 | $32 |
| New patient visit (60+ min) | 13 | $2,029 | $156 |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,470 | $43 |
2021: 14 services
| Injection, aflibercept, 1 mg | 88 | $263,761 | None |
| Injection of drug into eye | 118 | $22,877 | $105 |
| Injection, ranibizumab, 0.1 mg | 13 | $21,971 | None |
| Imaging of retina | 305 | $16,608 | $37 |
| Short return visit (20+ min) | 158 | $15,393 | $81 |
| Established patient complete exam of visual system | 101 | $10,289 | $100 |
| New patient complete exam of visual system | 71 | $8,303 | $117 |
| Return visit (30+ min) | 60 | $7,868 | $98 |
| New patient visit (45+ min) | 45 | $6,761 | $150 |
| Photography of the retina | 108 | $4,501 | $30 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 37 | $4,196 | $113 |
| Established patient problem focused exam of visual system | 30 | $2,565 | $85 |
| Injection, bevacizumab, 10 mg | 13 | $1,300 | None |
| 2d ultrasound scan of eye tissue and structures | 13 | $666 | $42 |
2020: 5 services
| Established patient complete exam of visual system | 82 | $12,129 | $109 |
| Photography of the retina | 85 | $4,015 | $39 |
| New patient complete exam of visual system | 28 | $3,637 | $130 |
| Injection of drug into eye | 18 | $3,225 | $92 |
| Imaging of retina | 28 | $1,393 | $36 |
2019: 6 services
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 16 | $2,716 | $170 |
| Injection of drug into eye | 25 | $2,419 | $97 |
| Established patient complete exam of visual system | 25 | $1,791 | $69 |
| Imaging of retina | 35 | $718 | $20 |
| Emergency department visit with straightforward medical decision making | 15 | $456 | $30 |
| Examination of eye by ophthalmoscope with retinal drawing | 13 | $393 | $30 |
2018: 3 services
| Emergency department visit with moderate level of medical decision making | 12 | $1,190 | $99 |
| Emergency department visit with straightforward medical decision making | 16 | $522 | $33 |
| Imaging of retina | 11 | $273 | $23 |
Medicaid work
$307,875 in 2024
Medicaid paid $307,875 for 2,216 billed services this clinician did in 2024, up to 99 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 374 | $251,402 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 589 | $44,904 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 910 | $7,371 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 129 | $1,861 |
| Injection, bevacizumab, 10 mg | 21 | $860 |
| Short return visit (20+ min) | 64 | $740 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 129 | $738 |
| 2024 | 2,216 | 7 | 99 | $307,875 |
| 2023 | 2,680 | 8 | 98 | $384,150 |
| 2022 | 1,252 | 7 | 64 | $164,379 |
| 2021 | 915 | 7 | 40 | $64,184 |
| 2020 | 475 | 6 | 50 | $15,155 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 487 | $302,242 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 673 | $68,737 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,020 | $8,105 |
| Short return visit (20+ min) | 399 | $2,177 |
| Injection, bevacizumab, 10 mg | 34 | $1,791 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 41 | $844 |
| Return visit (30+ min) | 12 | $152 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 14 | $102 |
2022
| Aflibercept injection | 201 | $126,966 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 286 | $30,432 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 532 | $3,661 |
| Injection, bevacizumab, 10 mg | 47 | $1,772 |
| Short return visit (20+ min) | 143 | $786 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 29 | $706 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 14 | $55 |
2021
| Aflibercept injection | 26 | $33,721 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 281 | $10,007 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 114 | $8,990 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 279 | $4,475 |
| Return visit (30+ min) | 75 | $2,738 |
| Short return visit (20+ min) | 99 | $2,447 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 41 | $1,806 |
2020
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 168 | $5,555 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 167 | $5,125 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 59 | $2,398 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 21 | $1,398 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 43 | $627 |
| Injection, bevacizumab, 10 mg | 17 | $52 |
Drugs they prescribed that Part D paid
$15,769
Pharmacies billed $15,769 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 434) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
293 generic and 141 brand-name prescriptions · $15,769 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 132 | $4,100 | $31 |
| Bromfenac | 22 | $3,917 | $178 |
| Ketorolac Tromethamine | 107 | $1,900 | $18 |
| Difluprednate | 13 | $1,453 | $112 |
| Neomycin-Polymyxin-Dexameth | 78 | $779 | $10 |
See all 7 drugs
| Prednisolone Acetate | 132 | $4,100 | $31 |
| Bromfenac | 22 | $3,917 | $178 |
| Ketorolac Tromethamine | 107 | $1,900 | $18 |
| Difluprednate | 13 | $1,453 | $112 |
| Neomycin-Polymyxin-Dexameth | 78 | $779 | $10 |
| Dorzolamide-Timolol | 13 | $124 | $10 |
| Timolol Maleate | 16 | $74 | $5 |
Year by year
| 2024 | 434 | 112 | 0% (0) | 32% | $15,769 |
| 2023 | 430 | 94 | None | 33% | $23,291 |
| 2022 | 339 | 90 | None | 31% | $17,907 |
| 2021 | 199 | 55 | 0% (0) | 41% | $21,107 |
| 2020 | 245 | 88 | None | 47% | $15,442 |
| 2019 | 467 | 160 | None | 45% | $34,520 |
| 2018 | 502 | 179 | None | 49% | $48,734 |
| 2017 | 173 | 80 | None | 38% | $14,593 |
| 2016 | 66 | 46 | None | 27% | $4,353 |
| 2015 | 127 | 58 | None | 29% | $14,714 |
| 2014 | 36 | 18 | None | None | $1,826 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Prolensa | 14 | $6,187 | $442 |
| Prednisolone Acetate | 128 | $4,986 | $39 |
| Bromfenac | 20 | $3,928 | $196 |
| Ketorolac Tromethamine | 87 | $1,946 | $22 |
| Neomycin-Polymyxin-Dexameth | 59 | $771 | $13 |
| Dorzolamide-Timolol | 22 | $690 | $31 |
| Dorzolamide | 26 | $655 | $25 |
| Brimonidine | 11 | $119 | $11 |
| Sulfamethoxazole-Trimethoprim | 11 | $7 | $1 |
2022: 6 drugs
| Prednisolone Acetate | 86 | $3,154 | $37 |
| Ketorolac Tromethamine | 77 | $2,128 | $28 |
| Brimonidine | 22 | $1,016 | $46 |
| Neomycin-Polymyxin-Dexameth | 52 | $788 | $15 |
| Dorzolamide-Timolol | 19 | $751 | $40 |
| Dorzolamide | 26 | $541 | $21 |
2021: 5 drugs
| Brimonidine | 18 | $2,334 | $130 |
| Prednisolone Acetate | 37 | $1,601 | $43 |
| Ketorolac Tromethamine | 52 | $1,471 | $28 |
| Dorzolamide-Timolol | 12 | $561 | $47 |
| Latanoprost | 26 | $509 | $20 |
2020: 6 drugs
| Prednisolone Acetate | 62 | $2,008 | $32 |
| Moxifloxacin | 34 | $1,583 | $47 |
| Ketorolac Tromethamine | 35 | $1,048 | $30 |
| Atropine Sulfate | 24 | $984 | $41 |
| Dorzolamide-Timolol | 18 | $453 | $25 |
| Brimonidine | 17 | $276 | $16 |
2019: 10 drugs
| Prednisolone Acetate | 106 | $4,366 | $41 |
| Moxifloxacin | 51 | $2,200 | $43 |
| Brimonidine | 34 | $1,673 | $49 |
| Atropine Sulfate | 36 | $1,524 | $42 |
| Timolol Maleate | 20 | $1,217 | $61 |
| Dorzolamide-Timolol | 25 | $995 | $40 |
| Ketorolac Tromethamine | 45 | $779 | $17 |
| Latanoprost | 21 | $227 | $11 |
| Atorvastatin | 16 | $209 | $13 |
| Erythromycin | 12 | $133 | $11 |
2018: 12 drugs
| Azopt | 22 | $6,932 | $315 |
| Ilevro | 20 | $6,064 | $303 |
| Prednisolone Acetate | 88 | $4,997 | $57 |
| Timolol Maleate | 38 | $3,737 | $98 |
| Moxifloxacin | 45 | $2,481 | $55 |
| Brimonidine | 24 | $1,626 | $68 |
| Ketorolac Tromethamine | 36 | $901 | $25 |
| Latanoprost | 47 | $757 | $16 |
| Atropine Sulfate | 23 | $733 | $32 |
| Dorzolamide | 16 | $537 | $34 |
| Dorzolamide-Timolol | 16 | $451 | $28 |
| Erythromycin | 12 | $140 | $12 |
2017: 4 drugs
| Timolol Maleate | 14 | $1,039 | $74 |
| Prednisolone Acetate | 21 | $866 | $41 |
| Dorzolamide-Timolol | 21 | $509 | $24 |
| Latanoprost | 12 | $206 | $17 |
2016: 1 drug
| Erythromycin | 12 | $155 | $13 |
Money from drug and device companies
$385 in 2025
| 2025 | 4 | 7 | None | $385 |
| 2024 | 8 | 12 | $1,788 | $2,156 |
| 2023 | 10 | 20 | $5,300 | $6,056 |
| 2022 | 5 | 17 | $6,345 | $7,854 |
| 2021 | 3 | 5 | None | $499 |
| 2020 | 1 | 1 | $350 | $350 |
| 2019 | 5 | 11 | None | $1,741 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $159 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $115 | 3 payments
|
| Genentech USA | Vabysmo | $69 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $42 | 1 payment
|
See all 7 published payments
| Genentech USA | Meals · 2025-10-07 | Vabysmo | $35 |
| Genentech USA | Meals · 2025-08-11 | Vabysmo | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-07-08 | Eylea Hd | $40 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $159 |
| Regeneron Healthcare Solutions | Meals · 2025-05-12 | Eylea Hd | $36 |
| Regeneron Healthcare Solutions | Meals · 2025-01-30 | Eylea Hd | $39 |
| Regeneron Pharmaceuticals | Meals · 2025-01-16 | Eylea Hd | $42 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,156
| Carl Zeiss Meditec | Cirrus 6000 With Angioplex | $1,138 | 2 payments
|
| Carl Zeiss Meditec USA | Cirrus Hd-Oct | $650 | 1 payment
|
| Genentech USA | Vabysmo | $119 | 4 payments
|
| RxSight | Rxsight Contact Lens | $114 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $63 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $25 | 1 payment
|
| Alimera Sciences | Yutiq | $24 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
2023: $6,056
| Carl Zeiss Meditec | Cirrus Hd-Oct | $5,300 | 3 payments
|
| Genentech USA | Vabysmo | $260 | 5 payments
|
| Oculus Surgical | None | $183 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $100 | 2 payments
|
| AbbVie | Ozurdex | $65 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $52 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $33 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $24 | 1 payment
|
| Alcon Vision | Centurion | $22 | 1 payment
|
| Carl Zeiss Meditec USA | Cirrus Hd-Oct | $18 | 1 payment
|
2022: $7,854
| Genentech USA | Vabysmo | $7,497 | 11 payments
|
| Genentech | Susvimo | $169 | 2 payments
|
| Apellis Pharmaceuticals | None | $124 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $45 | 2 payments
|
| Alimera Sciences | Iluvien | $19 | 1 payment
|
2021: $499
| Genentech USA | Lucentis | $235 | 2 payments
|
| Glaukos | Istent Inject W | $137 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $127 | 1 payment
|
2020: $350
| Alimera Sciences | Iluvien | $350 | 1 payment
|
2019: $1,741
| Regeneron Pharmaceuticals | Eylea | $913 | 3 payments
|
| Alcon Vision | Constellation | $520 | 5 payments
|
| Topcon Medical Systems | Oct Triton | $252 | 1 payment
|
| Alimera Sciences | Iluvien | $35 | 1 payment
|
| Celgene | None | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran Or Cemdisiran Alone in Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2025 | This clinician | $802 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225443997
- Licence
- CA A174746, CT 65296California A174746: Current · expires 2027-09-30
- Trained
- Harvard Medical School, 2014
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2495 Hospital Dr Ste 545, Mountain View, CA, 94040
- NPI first listed
- 2014-06-21
- NPI last updated
- 2022-08-10
- NPI record certified
- 2022-08-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 40 Temple St, New Haven, CT, 06510